Roche | US investors (2024)

The Roche Group (of which Genentech is a wholly-owned member) is traded in the United States as a U.S.-dollar denominated American Depositary Receipt (“ADR”) on the OTCQX International Premier market under the stock symbol: RHHBY.

ADRs are U.S. dollar-denominated securities which represent ownership of equity in non-U.S. companies. The stocks of most foreign companies that trade in the U.S. markets are traded as ADRs issued by U.S. depositary banks.

The Roche ADRs trade, clear and settle just like any U.S.-listed company shares and can be bought or sold through any U.S. registered brokerage (including online brokerages such as TD Ameritrade, E-Trade, Scottrade, etc.). Roche ADR holders are entitled to dividend payments.

The underlying Roche Group security (Roche Holding AG) is listed on the SIX Swiss Exchange (Switzerland’s principal stock exchange) under the stock symbols stock symbols RO.SW (voting share) and ROG.SW (non-voting equity security) and adheres to strict financial reporting standards and regulations. Roche’s ADR (RHHBY) represents ownership of equity in ROG.SW, where eight (8) Roche ADRs represent one (1) underlying ROG non-voting equity security. Since ADRs are based on the common shares of the non-U.S. company, the price of an ADR will often move in sync with the price of the underlying common shares once the ADR to common share ratio and currency rate is considered.

Note a) The number of ADRs in issue varies depending on demand and conversion in and out of the underlying non-voting equity security (NES)

The Roche ADR facility was initiated in 1992 when one (1) ADR represented one hundredth (1/100) of one underlying non-voting equity security. The current ADR ratio is a result of several splits and ratio changes.

Note b) On 3 April 2001, the Board of Directors approved a 100 for 1 split of the non-voting equity security. This was followed by an opposite 1 for 100 change in the ADR to NES ratio. As a result, no new ADRs were distributed

Note c) Declared date is the date of approval of the proposed dividend at the Annual General Meeting

Note d) Ex-dividend date is the first date where trading takes place without dividend

Note e) Record date is the last date on which the security must be held in custody in order to be eligible to receive dividend (as settlement typically takes place trading day + 3 days)

Note f) Roche dividend to ADR holders will be paid in two stages. The first payment will be less 35% Swiss withholding tax, and payment fee of $0.0300 per ADR payable one week after Swiss pay date. Those eligible holders reclaiming Swiss withholding tax will receive a second payment once the reclaim process is completed (typically early May). For the amount listed in the net dividend column, a 15% tax rate has been assumed. Roche is considered a qualified foreign corporation for U.S. tax purposes. For further tax questions, please consult a tax advisor

An American Depositary Receipt (ADR) represents ownership in the shares of a non-U.S. company that trades in U.S. financial markets. The Roche ADR (stock symbol: RHHBY) allows U.S. investors to buy or trade locally in Roche Group shares, which are otherwise listed on the SIX Swiss Exchange.

The Roche ADR is denominated in U.S. dollars, allowing U.S. investors to realize any dividend or capital gains, where applicable, in U.S. dollars. The dividend tax reclaim process is also taken care of by J.P. Morgan, Roche’s depositary bank and simplified for investors (typically reducing dividend tax to the U.S. level, with the actual tax rate depending on the investor’s individual circ*mstances).

Global custodian safekeeping fees are also eliminated, which usually make holding the ADRs less expensive. Through the 8:1 split of the Roche ADR to its Swiss non-voting equity security, the price per ADR share is also lower and makes investing in Roche more accessible to individual investors.

In 2010, Roche initiated a dividend reinvestment program through the depositary bank, J.P. Morgan Chase, to all registered ADR holders. Through the plan, Roche ADR holders can arrange to reinvest all or part of their dividend in the purchase of additional ADRs. For more information, please see the brochure at the Learn more about section of this page.

In 2006, to facilitate expanded market access and secondary trading, the Roche ADR obtained a securities manual listing by Standard & Poor’s Standard Corporation Records.

Information about buying and selling the Roche ADR as well as information about dividend payments should be addressed to your bank or broker.

P. Morgan Chase sponsors and administers the Roche ADR facility. The J.P. Morgan ADR shareholder services can be contacted as follows:

Toll free number: Phone:1 800 990 1135
Hearing impaired: Phone:1 866 700 1652
Outside the U.S.: Phone:+1 651 453 2128
Email:

Regular correspondence:
EQ Shareowner Services
P.O. Box 64504
St. Paul, MN 55164-0504
Delivery of ADR certificates and overnight mail:
EQ Shareowner Services
1110 Centre Pointe Curve, Suite 101
Mendota Heights, MN 55120

Questions about Roche, its business and products should be addressed to Investor Relations North America:

Investor Relations North America
Roche Holdings, Inc.
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
USA
Phone (Main Number):
Fax Investors:
Email IR Team:

Information accessed herein may not under any circ*mstances be used for the purpose of, or in connection with, the quotation of any securities on an automated inter-dealer quotation system within the meaning of Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Roche | US investors (2024)

FAQs

Is Roche a good company to invest in? ›

Roche Holding AG - Sell

Valuation metrics show that Roche Holding AG may be fairly valued. Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of RHHBY, demonstrate its potential to perform inline with the market. It currently has a Growth Score of C.

Who is the biggest shareholder of Roche? ›

We note that hedge funds don't have a meaningful investment in Roche Holding. Andreas Oeri is currently the largest shareholder, with 5.2% of shares outstanding. In comparison, the second and third largest shareholders hold about 3.8% and 3.5% of the stock.

What is the Roche outlook for 2024? ›

Looking ahead for fiscal 2024, Roche still expects an increase in group sales in the mid single digit range at constant exchange rates. Core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, excluding the impact from resolution of tax disputes in 2023.

What is the outlook for Roche Pharmaceuticals? ›

RHHVF Stock 12 Month Forecast

Based on 11 Wall Street analysts offering 12 month price targets for Roche Holding AG in the last 3 months. The average price target is $273.68 with a high forecast of $312.27 and a low forecast of $230.09. The average price target represents a 14.36% change from the last price of $239.32.

Is Roche a good long-term investment? ›

Roche faces challenges with its pipeline and acquisitions but remains confident in its future growth prospects. A safe balance sheet and progressive dividend yield make the company a buy.

Why is Roche stock struggling? ›

Pandemic Impact

Roche's sales dropped 6% last quarter to 14.4 billion francs ($15.8 billion), held down by a strong Swiss franc and a lack of revenue from Covid-19 tests and treatments. Analysts surveyed by Bloomberg expected 14.6 billion francs.

How much debt is Roche Holdings in? ›

Compare RHHBY With Other Stocks
Roche Holding AG Quarterly Long Term Debt (Millions of US $)
2022-06-30$23,165
2021-12-31$17,589
2021-06-30$12,037
2020-12-31$10,901
25 more rows

Is Roche stock undervalued? ›

The intrinsic value of one ROG stock under the Base Case scenario is 340.3 CHF. Compared to the current market price of 224 CHF, Roche Holding AG is Undervalued by 34%.

How much of Roche is owned by family? ›

The deal will boost the voting power of the Roche founding families to about 67.5%, Roche said. The family's current voting stake is about 45%, according to the company's 2020 annual report.

Is Roche laying off? ›

Roche has confirmed that it plans to lay off several hundred employees from its product development team, but it has not given specific details.

Why is Roche share price so low? ›

Roche stock has been weighed down in the recent past due to some pipeline failures, including the Alzheimer's treatment - Gantenerumab. Roche has been looking at inorganic growth to bolster its pipeline.

Who is the CEO of Roche? ›

Why did Novartis sell Roche? ›

Sale of the stake will therefore provide a cash windfall that Novartis believes will help further build on its strategy. “After more than 20 years as a shareholder of Roche, we concluded that now is the right time to monetize our investment,” Narasimhan said in a Nov. 4 statement.

What is Roche top salary? ›

Roche Diagnostics Salary
Annual SalaryHourly Wage
Top Earners$84,000$40
75th Percentile$74,000$36
Average$64,003$31
25th Percentile$53,000$25

Why does Novartis own Roche? ›

Novartis acquired the stake between 2001 and 2003 for a total consideration of approximately USD 5 billion as a long-term financial investment which delivered significant, recurring earnings contribution and cumulative dividends in excess of USD 6 billion.

Is PFE a good long-term investment? ›

Stock to Watch: Pfizer (PFE)

PFE is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 11.37; value investors should take notice.

What is the riskiest company to invest in? ›

6 High-Risk Stocks for Aggressive Investors
  • Yum China Holdings Inc. (ticker: YUMC)
  • Albemarle Corp. (ALB)
  • Walgreens Boots Alliance Inc. (WBA)
  • Ubiquiti Inc. (UI)
  • Chewy Inc. (CHWY)
  • Concentrix Corp. (CNXC)
Apr 30, 2024

Why is Roche underperforming? ›

Roche's stock price has declined, underperforming its peers, due to the loss of patent protection for its blockbuster drugs, lower Covid-related revenue and several pipeline setbacks. The company has developed second-generation drugs and expanded into new therapeutic areas to offset the decline in revenue.

What is Roche stock forecast for 2030? ›

The forecasted annual earnings of Roche Holding AG - Depositary Receipt (Common Stock) in 2030-12-31 is 35.57 per share.

Top Articles
Latest Posts
Article information

Author: Eusebia Nader

Last Updated:

Views: 5962

Rating: 5 / 5 (60 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Eusebia Nader

Birthday: 1994-11-11

Address: Apt. 721 977 Ebert Meadows, Jereville, GA 73618-6603

Phone: +2316203969400

Job: International Farming Consultant

Hobby: Reading, Photography, Shooting, Singing, Magic, Kayaking, Mushroom hunting

Introduction: My name is Eusebia Nader, I am a encouraging, brainy, lively, nice, famous, healthy, clever person who loves writing and wants to share my knowledge and understanding with you.